PH
Amgen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MariTide (AMG 133) | Obesity / Weight Management | Phase 2 |
| Olpasiran (AMG 890) | Elevated Lipoprotein(a) for Cardiovascular Risk Reduction | Phase 3 |
| Tarlatamab (AMG 757) | Small Cell Lung Cancer (SCLC) | Phase 3 |
| ABP 938 | Ophthalmology (Biosimilar to Eylea) | Phase 3 |
| TEZSPIRE (tezepelumab) | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 |
| LUMAKRAS/LUMYKRAS (sotorasib) | KRAS G12C-mutated Non-Small Cell Lung Cancer | Phase 3 |